Rakovina Therapeutics (TSXV:RKV) ROCE % : -78.58% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Rakovina Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Rakovina Therapeutics's annualized ROCE % for the quarter that ended in Sep. 2024 was -78.58%.

Rakovina Therapeutics ROCE % Historical Data

The historical data trend for Rakovina Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rakovina Therapeutics ROCE % Chart

Rakovina Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-28.96

-38.34

-44.74

Rakovina Therapeutics Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial										-39.25	-49.51	-59.18	-63.66	-78.58

Rakovina Therapeutics ROCE % Calculation

Rakovina Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-2.462	/	( ( (6.121 - 0.107)	+	(5.148 - 0.155) )	/ 2 )
	=	-2.462	/	( (6.014	+	4.993)	/ 2 )
	=	-2.462	/	5.5035
	=	-44.74 %

Rakovina Therapeutics's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-3.792	/	( ( (6.227 - 1.046)	+	(5.308 - 0.838) )	/ 2 )
	=	-3.792	/	( ( 5.181	+	4.47 )	/ 2 )
	=	-3.792	/	4.8255
	=	-78.58 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Rakovina Therapeutics (TSXV:RKV) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Rakovina Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Rakovina Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Rakovina Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (TSXV:RKV) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

RKVTF:USA 7JO:Germany

Address

595 Burrard Street, P.O. Box 49314, Suite 2600, Three Bentall Centre, Vancouver, BC, CAN, V6B 0A5

Website

https://www.rakovinatherapeutics.com

Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some of its products in the pipeline include kt-2000 AI, kt-3000 series. Rakovina gained exclusive use of the Deep Docking AI Platform, enabling it to significantly speed up identifying potential drugs for DNA damage response.

Executives

Alfredo De Lucrezia	Director, Senior Officer
Michael Liggett	Director
Jeffrey Bacha	Senior Officer
Mads Daugaard	Senior Officer
David Hyman	Senior Officer
John Michael Langlands	Senior Officer

Rakovina Therapeutics Headlines

No Headlines